Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-04-20 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the eighth meeting of the fourth board of directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes multiple agenda items such as approval of the 2024 board work report, general manager's work report, 2024 annual report and summary, financial reports, remuneration proposals, dividend distribution plans, changes to the articles of association, audit reports, internal control reports, and appointment of auditors. The document also references that the actual 2024 annual report and other detailed reports are published separately on the Beijing Stock Exchange information disclosure platform. The document is a formal board meeting resolution announcement, not the annual report itself. It contains detailed board decisions and voting results but does not include the full financial statements or substantive financial data of the annual report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management information.
2025-04-20 Chinese
拟续聘2025年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (中汇会计师事务所) as the auditor for the fiscal year 2025. It details the auditor's background, service history, fees, and the approval process by the board and audit committee. There are no financial statements or audit reports included, only information about the auditor appointment process. The document length is 2619 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement related to auditor appointment, not the audit report itself. FY 2025
2025-04-20 Chinese
2024年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Plan Announcement" for the year 2024 by Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the proposed dividend distribution plan, including cash dividends and stock dividends, referencing the audited 2024 annual report. The document includes the board, supervisory committee, and independent directors' opinions on the dividend plan, the company's dividend policy, and legal compliance. It also mentions that the plan requires approval at the 2024 annual shareholders meeting. The document is 3959 characters long, which is relatively short and primarily serves as an announcement of the dividend distribution plan rather than the full annual report or financial statements. It does not contain comprehensive financial data or full report content but rather the dividend proposal and related governance information. Therefore, it fits best under the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2025-04-20 Chinese
山西锦波生物医药股份有限公司关于获得第三类医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate issued by the National Medical Products Administration. It details the product name, registration number, registrant information, approval date, and the impact on the company. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no legal proceedings, or other report types. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-04-09 Chinese
第四届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the seventh meeting of the fourth board of directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results on a specific company policy regarding market value management. There is no financial data, earnings information, or report publication mentioned. The content focuses on board meeting decisions and governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2025-02-26 Chinese
2024年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2024 年年度业绩快报公告' which translates to '2024 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2024, including revenue, profit, earnings per share, and asset information. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be disclosed in the 2024 Annual Report. The document is relatively short (2030 characters) and serves as a quick earnings summary rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of report publication but a brief financial performance update. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2024
2025-02-23 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.